Relmada Therapeutics, Inc. (RLMD)
USD 0.35
(-2.32%)
USD 0.35
(-2.32%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -51.65 Million | -103.8 Million | -91.87 Million | -27.8 Million | -12.09 Thousand | -10.49 Million |
| Net Income | -98.79 Million | -157.04 Million | -125.75 Million | -59.45 Million | -15 Thousand | -17.31 Million |
| Depreciation & Amortization | - | - | 1258.00 | 3752.00 | 4.36 | 4870.00 |
| Deferred income taxes | - | - | - | - | - | 3.82 Million |
| Stock-based compensation | 43.81 Million | 44.19 Million | 40.49 Million | 20.77 Million | 2761.70 | 1.21 Million |
| Change in working capital | 3.08 Million | 10.59 Million | -7.86 Million | 10.84 Million | -26.46 | 1.5 Million |
| Other non-cash items | 241.15 Thousand | -1.54 Million | 1.24 Million | 16.94 Thousand | 172.81 | 266.75 Thousand |
| Investing Cash Flow | 50.45 Million | 19.73 Million | -54.11 Million | -34.44 Million | -80.16 Thousand | - |
| Investments in PPE | -4.00 | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -90.46 Million | -47.29 Million | -222.98 Million | -182.05 Million | - | - |
| Sales/Maturities of investments | 140.91 Million | 67.02 Million | 168.86 Million | 147.6 Million | - | - |
| Other Investing Activities | 50.45 Thousand | 19.73 Thousand | -54.11 Thousand | -34.44 Thousand | -80.16 Thousand | - |
| Financing Cash Flow | -98.46 Thousand | 45.02 Million | 187.93 Million | 28.47 Million | 126.1 Thousand | 17.47 Million |
| Debt repayment | - | - | - | -110.24 Thousand | - | -285.17 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 43.43 Million | 185.31 Million | 20.52 Million | - | 17.76 Million |
| Other Financing Activities | -98.46 Thousand | 1.58 Million | 2.62 Million | 8.05 Million | 126.1 Thousand | - |
| Accounts receivables | 512.43 Thousand | -426.05 Thousand | 79.45 Thousand | - | - | -169.36 Thousand |
| Accounts payables | -1.75 Million | 421.04 Thousand | 2.84 Million | 7.82 Million | - | 158.92 Thousand |
| Inventory | - | 426.05 Thousand | -79.45 Thousand | - | - | 169.36 Thousand |
| Other working capital | 4.32 Million | 10.17 Million | -10.71 Million | 3.02 Million | -26.46 | 1.34 Million |
| Cash at beginning of period | 5.39 Million | 44.44 Million | 2.49 Million | 36.27 Million | 2238.94 | 2.23 Million |
| Cash at end of period | 4.09 Million | 5.39 Million | 44.44 Million | 2.49 Million | 9216.55 | 9.21 Million |
| Capital Expenditure | -4.00 | - | - | - | - | - |
| Effect of forex changes on cash | -1.00 | - | - | - | -26.87 Thousand | - |
| Net cash flow / Change in cash | -1.3 Million | -39.04 Million | 41.94 Million | -33.78 Million | 6977.61 | 6.97 Million |
| Free Cash Flow | -51.65 Million | -103.8 Million | -91.87 Million | -27.8 Million | -12.09 Thousand | -10.49 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -17.76 Million | -21.82 Million | -25.16 Million | -98.79 Million | -22 Million | -25.3 Million |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 7.21 Million | 8.29 Million | 9.89 Million | 43.81 Million | 11.39 Million | 11.16 Million |
| Change in working capital | -2.62 Million | 599.75 Thousand | 5.42 Million | 3.08 Million | -1.65 Million | 220.53 Thousand |
| Other non-cash items | 8.14 Million | 6.5 Million | -404.93 Thousand | 241.15 Thousand | 630.86 Thousand | 639.63 Thousand |
| Investing Cash Flow | 14.01 Million | 10.05 Million | 7.74 Million | 50.45 Million | 3.86 Million | -1.15 Million |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -1.29 Million | -7.01 Million | -33.31 Million | -90.46 Million | -11.57 Million | -10.81 Million |
| Sales/Maturities of investments | 15.31 Million | 17.07 Million | 41.05 Million | 140.91 Million | 15.43 Million | 9.65 Million |
| Other Investing Activities | 14.01 Thousand | 10.05 Thousand | 7741.15 | 50.45 Thousand | 3860.37 | -1151.74 |
| Financing Cash Flow | - | 221.74 Thousand | -98.46 Thousand | -98.46 Thousand | - | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 246.74 Thousand | - | - | - | - |
| Other Financing Activities | - | -25 Thousand | -98.46 Thousand | -98.46 Thousand | - | - |
| Accounts receivables | - | - | -512.43 Thousand | 512.43 Thousand | - | - |
| Accounts payables | -1.01 Million | 1.68 Million | 649.25 Thousand | -1.75 Million | -1.99 Million | 431.65 Thousand |
| Inventory | - | - | 512.43 Thousand | - | - | - |
| Other working capital | -1.6 Million | -1.08 Million | 4.77 Million | 4.32 Million | 343.99 Thousand | -211.11 Thousand |
| Cash at beginning of period | 1.33 Million | 4.09 Million | 6.69 Million | 5.39 Million | 14.46 Million | 28.89 Million |
| Cash at end of period | 2.08 Million | 1.33 Million | 4.09 Million | 4.09 Million | 6.69 Million | 14.46 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | -1.00 | -1.00 | - | - |
| Net cash flow / Change in cash | 751.24 Thousand | -2.75 Million | -2.6 Million | -1.3 Million | -7.77 Million | -14.42 Million |
| Free Cash Flow | -13.26 Million | -13.03 Million | -10.24 Million | -51.65 Million | -11.63 Million | -13.27 Million |
CBKD
SPSAF
1314
5363
2057
605099